FLGC Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -37.21% compared to Flora Growth Corp.'s net margin of -255.85%. Flora Growth Corp.'s return on equity of -77.18% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Flora Growth Corp. has a consensus price target of $20.50, signalling upside risk potential of 101.97%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Flora Growth Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Flora Growth Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

Flora Growth Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Flora Growth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Flora Growth Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Flora Growth Corp. quarterly revenues are $9.7M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Flora Growth Corp.'s net income of -$3.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Flora Growth Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Flora Growth Corp. is 1.06x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -37.21% compared to Flora Growth Corp.'s net margin of --. Flora Growth Corp.'s return on equity of -77.18% beat Palatin Technologies's return on equity of --.

Flora Growth Corp. has a consensus price target of $20.50, signalling upside risk potential of 101.97%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Flora Growth Corp., analysts believe Palatin Technologies is more attractive than Flora Growth Corp..

Flora Growth Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Flora Growth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Flora Growth Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Flora Growth Corp. quarterly revenues are $9.7M, which are larger than Palatin Technologies quarterly revenues of --. Flora Growth Corp.'s net income of -$3.6M is higher than Palatin Technologies's net income of --. Notably, Flora Growth Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Flora Growth Corp. is 1.06x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Tharimmune, Inc. has a net margin of -37.21% compared to Flora Growth Corp.'s net margin of --. Flora Growth Corp.'s return on equity of -77.18% beat Tharimmune, Inc.'s return on equity of -514.29%.

Flora Growth Corp. has a consensus price target of $20.50, signalling upside risk potential of 101.97%. On the other hand Tharimmune, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 109.21%. Given that Tharimmune, Inc. has higher upside potential than Flora Growth Corp., analysts believe Tharimmune, Inc. is more attractive than Flora Growth Corp..

Flora Growth Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tharimmune, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Flora Growth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tharimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Flora Growth Corp. pays -- of its earnings as a dividend. Tharimmune, Inc. pays out -- of its earnings as a dividend.

Flora Growth Corp. quarterly revenues are $9.7M, which are larger than Tharimmune, Inc. quarterly revenues of --. Flora Growth Corp.'s net income of -$3.6M is lower than Tharimmune, Inc.'s net income of -$2.1M. Notably, Flora Growth Corp.'s price-to-earnings ratio is -- while Tharimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Flora Growth Corp. is 1.06x versus -- for Tharimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -37.21% compared to Flora Growth Corp.'s net margin of --. Flora Growth Corp.'s return on equity of -77.18% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Flora Growth Corp. has a consensus price target of $20.50, signalling upside risk potential of 101.97%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than Flora Growth Corp., analysts believe Theriva Biologics, Inc. is more attractive than Flora Growth Corp..

Flora Growth Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Flora Growth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Flora Growth Corp. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Flora Growth Corp. quarterly revenues are $9.7M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Flora Growth Corp.'s net income of -$3.6M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Flora Growth Corp.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Flora Growth Corp. is 1.06x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.